Researchers at Winship Cancer Institute of Emory University and collaborating institutions have identified differences in the bone marrow immune environment of patients with multiple myeloma that are associated with African genetic ancestry.

A biomarker-driven pilot study with first-in-class treatment led by Winship researchers in collaboration with scientists at Vaccinex, Inc. shows how targeting SEMA4D may help immune cells organize inside melanoma tumors and work more effectively with immunotherapy.

Clara Farley, MD, a breast surgical oncologist at Winship, has performed Georgia’s first robotic nipple-sparing mastectomy outside a clinical trial, bringing a new minimally invasive surgical option to select patients with breast cancer.

Winship is first in the world to enhance cancer care with new endovascular robotics technology

Winship Cancer Institute of Emory University has been awarded a five-year, $10.9 million Specialized Program of Research Excellence (SPORE) grant from the National Cancer Institute (NCI) to advance new approaches for lung cancer treatment.

Researchers at Winship Cancer Institute of Emory University have discovered that B cells—immune cells best known for producing antibodies—can help train cancer-fighting T cells while those cells are being prepared for treatment.

A pivotal Phase 3 clinical trial led by Winship physician-scientist Sagar Lonial, MD, FACP, FASCO, contributed to accelerated approval by the U.S. Food and Drug Administration of iberdomide, the first therapy in a new CELMoD class for relapsed or refractory multiple myeloma.

Winship-led analysis of the landmark RxPONDER trial finds AMH, a blood marker commonly used to measure ovarian reserve, may better predict chemotherapy benefit in premenopausal women with breast cancer.

The innovative Trans-Arterial Micro-Perfusion (TAMP) therapy platform, available at Winship Cancer Institute, delivers targeted therapeutic agents, like chemotherapy, directly near the tumor for patients with locally advanced pancreatic cancer.

Winship Cancer Institute becomes first in Georgia, second nationally, to offer innovative theranostic clinical trial for patients with small cell lung cancer and other solid tumors.

Researchers at Winship Cancer Institute of Emory University have developed an “armored” form of CAR T-cell therapy designed to remain active longer and recruit additional immune cells to help attack cancer.

Atlantans reflect on the memories and unexpected moments from the Centennial Olympic Games that shaped their lives.

Atlantans reflect on the memories and unexpected moments from the Centennial Olympic Games that shaped their lives.

From immunotherapy breakthroughs to AI-driven innovations, Winship Cancer Institute of Emory University investigators will present emerging research at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, May 29 – June 2.

Shirish Gadgeel, MBBS, FASCO, a nationally recognized thoracic oncologist and clinical researcher, joins Emory University School of Medicine and Winship Cancer Institute as professor and vice chair for clinical research in the Department of Hematology and Medical Oncology.

Winship researcher Ravi B. Parikh, MD, is a co-author of an article in the New England Journal of Medicine examining the legal, ethical and patient safety questions raised by a Utah program testing whether artificial intelligence can independently renew prescriptions for certain chronic conditions.

Winship's first annual Translational Cancer Metabolism Initiative (TCMI) Symposium served as a broader introduction to the initiative and showcased innovative cancer metabolism research through podium presentations and a poster session.

Researchers at Winship Cancer Institute and their collaborators published a new scientific review in JAMA that examines how excess body fat may influence cancer development and what current evidence suggests about reducing risk.

Three Atlanta health care leaders reshape men's health through robotic surgery innovation, mobile cancer screening and addiction recovery programs.

Researchers at Winship Cancer Institute of Emory University and Emory University School of Medicine have reported a significant advance in the development of next-generation anticancer therapeutics: a precision “molecular glue” strategy that converts previously undruggable cancer mutations into actionable drug targets.